276 related articles for article (PubMed ID: 10709889)
1. Pamidronate treatment of bone fibrous dysplasia in nine children with McCune-Albright syndrome.
Lala R; Matarazzo P; Bertelloni S; Buzi F; Rigon F; de Sanctis C
Acta Paediatr; 2000 Feb; 89(2):188-93. PubMed ID: 10709889
[TBL] [Abstract][Full Text] [Related]
2. Pamidronate treatment in bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome.
Matarazzo P; Lala R; Masi G; Andreo M; Altare F; de Sanctis C
J Pediatr Endocrinol Metab; 2002; 15 Suppl 3():929-37. PubMed ID: 12199352
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonate treatment of bone fibrous dysplasia in McCune-Albright syndrome.
Lala R; Matarazzo P; Andreo M; Marzari D; Bellone J; Corrias A; de Sanctis C;
J Pediatr Endocrinol Metab; 2006 May; 19 Suppl 2():583-93. PubMed ID: 16789621
[TBL] [Abstract][Full Text] [Related]
4. Intravenous pamidronate treatment of polyostotic fibrous dysplasia associated with the McCune Albright syndrome.
Zacharin M; O'Sullivan M
J Pediatr; 2000 Sep; 137(3):403-9. PubMed ID: 10969268
[TBL] [Abstract][Full Text] [Related]
5. [Effect of pamidronate on clinical symptoms and bone metabolism in fibrous dysplasia and McCune-Albright syndrome].
Pfeilschifter J; Ziegler R
Med Klin (Munich); 1998 Jun; 93(6):352-9. PubMed ID: 9662942
[TBL] [Abstract][Full Text] [Related]
6. Bone turnover in children and adolescents with McCune-Albright syndrome treated with pamidronate for bone fibrous dysplasia.
Isaia GC; Lala R; Defilippi C; Matarazzo P; Andreo M; Roggia C; Priolo G; de Sanctis C
Calcif Tissue Int; 2002 Aug; 71(2):121-8. PubMed ID: 12200645
[TBL] [Abstract][Full Text] [Related]
7. Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment.
Chapurlat RD; Hugueny P; Delmas PD; Meunier PJ
Bone; 2004 Jul; 35(1):235-42. PubMed ID: 15207763
[TBL] [Abstract][Full Text] [Related]
8. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone.
Chapurlat RD; Delmas PD; Liens D; Meunier PJ
J Bone Miner Res; 1997 Oct; 12(10):1746-52. PubMed ID: 9333137
[TBL] [Abstract][Full Text] [Related]
9. Pamidronate treatment of polyostotic fibrous dysplasia: failure to prevent expansion of dysplastic lesions during childhood.
Chan B; Zacharin M
J Pediatr Endocrinol Metab; 2006 Jan; 19(1):75-80. PubMed ID: 16509531
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonate-induced zebra lines in fibrous dysplasia of bone: histo-radiographic correlation in a case of McCune-Albright syndrome.
Corsi A; Ippolito E; Robey PG; Riminucci M; Boyde A
Skeletal Radiol; 2017 Oct; 46(10):1435-1439. PubMed ID: 28660402
[TBL] [Abstract][Full Text] [Related]
11. Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone.
Plotkin H; Rauch F; Zeitlin L; Munns C; Travers R; Glorieux FH
J Clin Endocrinol Metab; 2003 Oct; 88(10):4569-75. PubMed ID: 14557424
[TBL] [Abstract][Full Text] [Related]
12. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone.
Liens D; Delmas PD; Meunier PJ
Lancet; 1994 Apr; 343(8903):953-4. PubMed ID: 7909013
[TBL] [Abstract][Full Text] [Related]
13. Pamidronate for fibrous dysplasia due to McCune Albright Syndrome.
Kochar IP; Kulkarni KP
Indian Pediatr; 2010 Jul; 47(7):633-5. PubMed ID: 20683120
[No Abstract] [Full Text] [Related]
14. Craniofacial fibrous dysplasia: A 10-case series.
Couturier A; Aumaître O; Gilain L; Jean B; Mom T; André M
Eur Ann Otorhinolaryngol Head Neck Dis; 2017 Sep; 134(4):229-235. PubMed ID: 28302454
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonate therapy for fibrous dysplasia.
DiMeglio LA
Pediatr Endocrinol Rev; 2007 Aug; 4 Suppl 4():440-5. PubMed ID: 17982393
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of antiresorptive agents in fibrous dysplasia and McCune Albright syndrome, a systematic review and meta-analysis.
Bertin H; Moussa MS; Komarova S
Rev Endocr Metab Disord; 2023 Dec; 24(6):1103-1119. PubMed ID: 37632645
[TBL] [Abstract][Full Text] [Related]
17. EFFICACY AND SAFETY OF BISPHOSPHONATE THERAPY IN MCCUNE-ALBRIGHT SYNDROME-RELATED POLYOSTOTIC FIBROUS DYSPLASIA: A SINGLE-CENTER EXPERIENCE.
Wang Y; Wang O; Jiang Y; Li M; Xia W; Meng X; Xing X
Endocr Pract; 2019 Jan; 25(1):23-30. PubMed ID: 30383490
[TBL] [Abstract][Full Text] [Related]
18. Effect of intravenous pamidronate on bone markers and local bone mineral density in fibrous dysplasia.
Parisi MS; Oliveri B; Mautalen CA
Bone; 2003 Oct; 33(4):582-8. PubMed ID: 14555262
[TBL] [Abstract][Full Text] [Related]
19. Outcome of Long-Term Bisphosphonate Therapy in McCune-Albright Syndrome and Polyostotic Fibrous Dysplasia.
Majoor BC; Appelman-Dijkstra NM; Fiocco M; van de Sande MA; Dijkstra PS; Hamdy NA
J Bone Miner Res; 2017 Feb; 32(2):264-276. PubMed ID: 27649526
[TBL] [Abstract][Full Text] [Related]
20. Clinical, endocrinological and radiography features in a child with McCune-Albright syndrome and pituitary adenoma.
Zumkeller W; Jassoy A; Lebek S; Nagel M
J Pediatr Endocrinol Metab; 2001 May; 14(5):553-9. PubMed ID: 11393578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]